Evandro de Azambuja, MD, PhD· @E_de_Azambuja · X·· 21 小时前评分70
正文 · 原文
Anbenitamab + HB1801 has better PFS than THP as first line therapy (control arm did poorly 14.3 mos)
#ESMO26
#ESMOAmbassadors
#ESMOcommunity
@myESMO
23 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80按 Rapid oral 1: Gastrointestinal tumour, upper digestive 对上
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.org来源：Evandro de Azambuja, MD, PhD · x.com